UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
La revue de medecine interne, ISSN 0248-8663, 06/2017, Volume 38, p. A205
Journal Article
La revue de medecine interne, ISSN 0248-8663, 06/2017, Volume 38, pp. A205 - A206
Journal Article
Journal of thermal analysis and calorimetry, ISSN 1388-6150, 03/2014, Volume 115, Issue 3, p. 2369
Journal Article
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 7/2011, Volume 333, Issue 6041, pp. 459 - 462
Protein isoforms | Molecules | Molecular structure | DNA | Drug interactions | REPORTS | Antineoplastics | Biochemistry | Nucleotides | Genetic mutation | Monomers | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Structure in molecular biology | Molecular biophysics | Crystalline structure | Humans | Protein Multimerization | Crystallography, X-Ray | Drug Resistance, Neoplasm | Structure-Activity Relationship | DNA-Binding Proteins - metabolism | Topoisomerase II Inhibitors - chemistry | DNA Topoisomerases, Type II - chemistry | Protein Structure, Quaternary | Protein Structure, Tertiary | DNA Topoisomerases, Type II - metabolism | Catalytic Domain | Etoposide - analogs & derivatives | Etoposide - pharmacology | Models, Molecular | Etoposide - metabolism | Mutant Proteins - metabolism | Topoisomerase II Inhibitors - pharmacology | DNA - metabolism | Topoisomerase II Inhibitors - metabolism | DNA-Binding Proteins - genetics | DNA-Binding Proteins - chemistry | DNA - chemistry | Base Pairing | Mutant Proteins - chemistry | DNA Topoisomerases, Type II - genetics | Etoposide - chemistry | Mutation | Antimitotic agents | Topoisomerases | Etoposide | Physiological aspects | Research | Antineoplastic agents | Health aspects | Proteins | Enzymes | Pharmacology | Deoxyribonucleic acid--DNA | Cancer | Index Medicus
Journal Article
ACS nano, ISSN 1936-0851, 03/2018, Volume 12, Issue 3, pp. 2426 - 2439
polymeric micelles | nanomedicine | etoposide | drug delivery | cisplatin | chemotherapy | Cancer | Physical Sciences | Chemistry | Materials Science | Nanoscience & Nanotechnology | Technology | Materials Science, Multidisciplinary | Science & Technology - Other Topics | Chemistry, Multidisciplinary | Chemistry, Physical | Science & Technology | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cisplatin - pharmacokinetics | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Drug Carriers - chemistry | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Cisplatin - administration & dosage | Micelles | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Etoposide - pharmacology | Etoposide - administration & dosage | Etoposide - therapeutic use | Cisplatin - pharmacology | Drug Synergism | Animals | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Polymers - chemistry | Carcinoma, Non-Small-Cell Lung - drug therapy | Etoposide - pharmacokinetics | cancer
Journal Article
Apoptosis (London), ISSN 1360-8185, 06/2008, Volume 13, Issue 6, p. 756
Journal Article
Life sciences (1973), ISSN 0024-3205, 03/2017, Volume 172, pp. 1 - 1
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2010, Volume 53, Issue 7, pp. 2814 - 2824
Doxorubicin - therapeutic use | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Humans | Brain Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Doxorubicin - chemistry | Brain Neoplasms - metabolism | Antineoplastic Agents - metabolism | Brain - metabolism | Peptides - metabolism | Peptides - toxicity | Biological Transport | Doxorubicin - analogs & derivatives | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Doxorubicin - metabolism | Amino Acid Sequence | Brain - cytology | Etoposide - toxicity | Etoposide - analogs & derivatives | Peptides - chemistry | Etoposide - pharmacology | Etoposide - metabolism | Etoposide - therapeutic use | Antineoplastic Agents - chemistry | Brain Neoplasms - drug therapy | Blood-Brain Barrier - drug effects | Blood-Brain Barrier - metabolism | Peptides - pharmacology | Animals | Brain - pathology | Cell Line, Tumor | Etoposide - chemistry | Mice | Kinetics | Cell Cycle - drug effects | Doxorubicin - pharmacology | Peptides - therapeutic use | Index Medicus
Journal Article
Chest, ISSN 0012-3692, 09/2020
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1929 - 1939
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Etoposide - adverse effects | Drug Administration Schedule | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Carboplatin - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Progression-Free Survival | Cisplatin - adverse effects | Female | Small Cell Lung Carcinoma - mortality | Aged | Etoposide | Care and treatment | Product development | Lung cancer | Analysis | Drugs | Radiation | Clinical trials | Metastasis | Cancer therapies | Randomization | Platinum | Immunotherapy | Safety | Neutropenia | Small cell lung carcinoma | Maintenance | Radiation therapy | Survival | Patients | Cisplatin | Response rates | Carboplatin | Irradiation | Ligands | Clinical medicine | Solid tumors | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of pharmaceutical sciences, ISSN 0022-3549, 07/2016, Volume 105, Issue 7, pp. 2114 - 2122
microporation | microdialysis | etoposide phosphate | transdermal | rabbit | etoposide | anti-cancer | chemotherapy | iontophoresis | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Chemistry, Medicinal | Chemistry, Multidisciplinary | Science & Technology | Rabbits | Etoposide - analogs & derivatives | Area Under Curve | Skin - metabolism | Etoposide - administration & dosage | Skin Absorption | Etoposide - blood | Administration, Cutaneous | Antineoplastic Agents - administration & dosage | Chromatography, High Pressure Liquid | Irritants | Drug Delivery Systems | Iontophoresis | Animals | Microdialysis | Swine | Antineoplastic Agents - blood | Organophosphorus Compounds - blood | Female | Antineoplastic Agents - pharmacokinetics | Organophosphorus Compounds - administration & dosage | Organophosphorus Compounds - pharmacokinetics | Etoposide - pharmacokinetics | Index Medicus
Journal Article
Pediatric blood & cancer, ISSN 1545-5009, 01/2021, Volume 68, Issue 1
Journal Article
Nature medicine, ISSN 1078-8956, 01/2007, Volume 13, Issue 1, pp. 54 - 61
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Dendritic Cells - immunology | Electrophoresis, Gel, Two-Dimensional | Immunoblotting | Antineoplastic Agents - therapeutic use | Protein Transport - drug effects | Calreticulin - genetics | Colonic Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | RNA Interference | Anthracyclines - pharmacology | Neoplasms, Experimental - immunology | Calreticulin - metabolism | Antigens, Differentiation - metabolism | Antineoplastic Agents - pharmacology | Cell Membrane - metabolism | Protein Phosphatase 1 | Cell Membrane - drug effects | Mitomycin - therapeutic use | Cell Cycle Proteins - metabolism | Phagocytosis - immunology | Etoposide - pharmacology | Etoposide - therapeutic use | Recombinant Proteins - pharmacology | Mitomycin - pharmacology | Animals | Apoptosis - immunology | Mice, Nude | Colonic Neoplasms - pathology | Cell Line, Tumor | Cell Membrane - immunology | Mice | Mice, Inbred BALB C | Anthracyclines - therapeutic use | Calreticulin - immunology | Neoplasms, Experimental - metabolism | Neoplasms, Experimental - drug therapy | Chemotherapy | Immunology | DNA damage | Rodents | Cancer | Apoptosis | Tumors | Index Medicus | Antigens, Differentiation | Cell Membrane | Anthracyclines | Dendritic Cells | Recombinant Proteins | Life Sciences | Calreticulin | Neoplasms, Experimental | Mitomycin | Etoposide | Antineoplastic Agents | Protein Transport | Phagocytosis | Cell Cycle Proteins | Colonic Neoplasms | Medicin och hälsovetenskap
Journal Article
EXCLI journal, 01/2015, Volume 14, pp. 95 - 108
Journal Article
British journal of haematology, ISSN 0007-1048, 04/2015, Volume 169, Issue 2, pp. 188 - 198
vincristine | and rituximab | large B‐cell lymphoma | cyclophosphamide | doxorubicin | dose‐adjusted‐EPOCH‐R (etoposide, prednisone | high‐risk patients | cell of origin | Dose-adjusted-EPOCH-R (etoposide, prednisone | Cyclophosphamide | And rituximab | Cell of origin | Large B-cell lymphoma | High-risk patients | Doxorubicin | Vincristine | Life Sciences & Biomedicine | Hematology | Science & Technology | Doxorubicin - therapeutic use | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Neoplasm Grading | Adult | Female | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Etoposide - therapeutic use | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Medical research | Anthracyclines | Corticosteroids | Analysis | Clinical trials | Medicine, Experimental | Etoposide | Lymphomas | Prednisone | Index Medicus
Journal Article